Skystar Bio-pharmaceutical Co. (fka SKBI)

[Renee]

SKBI registration revoked:

https://www.sec.gov/litigation/admin/2019/34-85550.pdf

[getmoreshares]

04/09/2019 08:54:15
12(j)Registration Revoked by SEC
04/09/2019 08:54:00
SKBI
Skystar Bio-Pharamaceutical Co Common Stock
Other

[Chefor]

Theres a chance this gets pumped today

[duratrader]

CE added at OTC

SKBI CE at OTC

[Renee]

SKBI SEC Suspension for Financials and Filing delinquencies:

https://www.sec.gov/litigation/suspensions/2017/34-80893.pdf

Order:

https://www.sec.gov/litigation/suspensions/2017/34-80893-o.pdf

Admin Proceeding:

https://www.sec.gov/litigation/admin/2017/34-80892.pdf

[surfer44]

Quarterly Report Will Be Late

http://ih.advfn.com/p.php?pid=nmona&article=72923479

[surfer44]

Quarterly Report Will Be Late

http://ih.advfn.com/p.php?pid=nmona&article=72217061

[236T568]

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)





State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant’s Quarterly Report on Form 10-Q for the fiscal period ended March 31, 2016 cannot be filed within the prescribed time period because (i) the Registrant has not yet filed an Annual Report on Form 10-K for the years ended December 31, 2014 and 2015, and (ii) the Registrant’s former auditor, Crowe Horwath (HK) CPA Limited (“Crowe”) terminated its relationship with the Company on March 31, 2016 and advised the Registrant that it was recalling its Auditor Reports dated April 1, 2013 and March 31, 2014 and that such reports should no longer be associated with the financial statements for the fiscal years ended December 31, 2012 and 2013. Although the Registrant engaged Wei Wei & Co., LLP as its auditor on April 6, 2016, Crowe’s resignation and recall of its reports will lead to additional delays in the preparation of the Registrant’s financial statements. Please see the Registrant’s 8-K dated March 31, 2016 for information about Crowe’s resignation and Wei’s appointment.

http://ih.advfn.com/p.php?pid=nmona&article=71495026&symbol=SKBI

[surfer44]

Amended 8-K

http://www.sec.gov/Archives/edgar/data/1076939/000114420416097201/v438228_8k-a.htm

[surfer44]

Annual Report Will Be Submitted Late

http://ih.advfn.com/p.php?pid=nmona&article=71108119

[Bob Stocks]

Went all in today...wish me luck

[236T568]

Looks, bad, real bad for scam company SKBI:

http://ih.advfn.com/p.php?pid=nmona&article=71027638


Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

In the March 31 Letter, Crowe notified the Company that it was recalling its Auditor Reports dated April 1, 2013 and March 31, 2014 and that such reports should no longer be associated with the financial statements for the fiscal years ended December 31, 2012 and 2013.

In its letter Crowe indicated that:

1. Crowe had to suspend audit fieldwork in December 2015 because the Company was unable to arrange visits with certain vendors, customers, logistics companies or with eth relevant State Tax Bureau; and

2. The Company did not provide Crowe with certain information requested by it, as specified in the letter attached hereto as Exhibit 7.1.




Crowe indicated that the foregoing caused Crowe to be unwilling to rely on management’s representations in connection with its audits of the consolidated financial statements and of the Company for December 31, 2014 and prior periods.

Neither the Audit Committee of the Board of Directors nor the officers of the Company discussed the matters disclosed in response to this Item 4.02 with Crowe.

The Company has provided Crowe with a copy of the foregoing disclosures and has requested that Crowe review such disclosures and provide a letter addressed to the SEC as specified by Item 4.02(c) of Form 8-K. When available, the Company will file as Exhibit 7.2 a copy of Crowe’s letter addressed to the SEC relating to the statements made by the Company in this Current Report on Form 8-K.

[tbirdman]

Ugly....

Final nail in the coffin on this scam.

http://ih.advfn.com/p.php?pid=nmona&article=71027638

[tbirdman]

Your robot spammer mis-posted ...this board is for the chiscam company "Skystar Bio-pharmaceutical Co."(SKBI).

[ClayTrader]

* * $SKYS Video Chart 04-01-16 * *

Link to Video - click here to watch the technical chart video

[236T568]

Ouch! 0.2101 and dropping!

[tbirdman]

GAME OVER BITCHEZ

[236T568]

FORM 25 - NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.


http://ih.advfn.com/p.php?pid=nmona&article=70499514&symbol=SKBI

[tbirdman]

$SKBI creeping back up...no shares available to re-short

[tbirdman]

Just can't trade technicals on otc china without doing some basic dd...I hope we save him from buying any more at least...

[236T568]

huh?

there is NO revenue growth for SKBI

the latest quarterly revenues DROPPED from $18 million to only $7 million

.my buys are based on price action technicals AND company fundamentals for skbi...I do like their revenue growth and major holders...in short I like the risk reward here...

[luvgrowth]

thanks...I know I will not get destroyed in skbi...too many big money hedgies i am a little familiar with still in skbi...lol...gl

[236T568]

So you are presenting 2014 figures?

we are now at the end of 2015 and SKBI has not issued financials since the Sept 2014 10Q


by the way, did you miss the part where the company stated in an 8K in an SEC filing that revenues at its latest quarter DROPPED from $18 million to only $7 million?

Period Ending 30-Sep-14 30-Jun-14 31-Mar-14 31-Dec-13
Total Revenue 18,353 14,240 6,833 9,625
Cost of Revenue 9,590 7,881 4,009 4,906
Gross Profit 8,763 6,359 2,823 4,720

(all numbers times 1000)
Nice q over q growth in gross profit...37.8%.
finance.yahoo.com/q/is?s=skbi

[tbirdman]

Good luck, from latest verbiage in filings revs are expected to drop 60%. If you don't do proper dd in the china sector you will get destroyed.

[luvgrowth]

...my buys are based on price action technicals AND company fundamentals for skbi...I do like their revenue growth and major holders...in short I like the risk reward here...

[tbirdman]

I hope you realize what you're buying...might want to catch up and read the latest filings..projected rev and cash position is UGLY (if they file).

[luvgrowth]

adding to skbi position...bot again at $0.53...target $1.03...gl

[luvgrowth]

Period Ending 30-Sep-14 30-Jun-14 31-Mar-14 31-Dec-13
Total Revenue 18,353 14,240 6,833 9,625
Cost of Revenue 9,590 7,881 4,009 4,906
Gross Profit 8,763 6,359 2,823 4,720

(all numbers times 1000)
Nice q over q growth in gross profit...37.8%.
http://finance.yahoo.com/q/is?s=skbi

[surfer44]

SKBI: Update

http://finance.yahoo.com/news/skystar-bio-pharmaceutical-company-151653188.html

[236T568]

Oh the Humanity! 0.41 and dropping!

[luvgrowth]

bot a starter today pps $0.61...gl

[236T568]

Ouch! 0.56 and dropping!

[tbirdman]

Timmmmmmberrrrrr

[236T568]

Skystar Bio-Pharmaceutical Company SKBI Regulatory/Non Compliance Suspended 12/21/2015


https://listingcenter.nasdaq.com/IssuersPendingSuspensionDelisting.aspx

[tbirdman]

Mark one down for the good guys :- )

[236T568]

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On December 17, 2015, Skystar Bio-Pharmaceutical Company (the “Company”) received a notification from The Nasdaq Stock Market (“Nasdaq”) informing the Company that a Nasdaq hearing panel had decided to delist the Company’s shares from Nasdaq and that the Company’s shares would be suspended from trading on Nasdaq at the open of business on December 21, 2015.

The Company previously disclosed a notification from Nasdaq informing the Company that is was subject to delisting because it failed to comply with Nasdaq’s filing requirements set forth in Listing Rule 5250(c)(1) because it failed to file its Form 10-K for the fiscal year ended December 31, 2014, and Forms 10-Q for the periods ended March 31, and June 30, 2015. The failure to file the Quarterly Report constitutes an additional basis for delisting. The Company also previously disclosed that Nasdaq had notified the Company of two additional, and separate, bases for delisting under Listing Rule 5250(b)(1) (failure to disclose material non-public information) and Listing Rule 5101 (public interest concerns).


http://ih.advfn.com/p.php?pid=nmona&article=69760863&symbol=SKBI

[236T568]

and how is that working out for you?

Regarding "disclosure of material information", Nasdaq twists this any way they want to, it's a freaking joke. Nasdaq is a freaking joke. Asif every company discloses the fact that some accountant made an error. The auditor noticed it (what they were hired to do) and they fixed it. Job done.

[236T568]

Summary
Date Event Type Eff/Ex Date Symbol Issue Name Market
12/18/2015 12:32:50 Market Center Change Delisted from NASDAQ
12/21/2015 00:00:00 SKBI Skystar Bio-Pharamaceutical Co Common Stock Other OTC

Comments
Moving from NASDAQ [SKBI]


Details
Current Value
Daily List Date 12/18/2015 12:32:50
Event Type Market Center Change Delisted from NASDAQ
Effective/Ex Date 12/21/2015 00:00:00
Issue Type
Symbol SKBI
Issue Name Skystar Bio-Pharamaceutical Co Common Stock
Class
ADR Ratio
Maturity Date
Market Category Other OTC
Offering Type No Restrictions
OATS Reportable (Rptbl) Flag Yes
Unit of Trade 100
Reg Fee Flag Yes
Daily List Comment Moving from NASDAQ [SKBI]

[tbirdman]

Weeeeee

[RealDutch]

Well, more evidence that the market is as blind as a bat.

[Renee]

SKBI delisted from the Nasdaq to the OTC:

http://otce.finra.org/DLAdditions

[tbirdman]

Who the *(&#$ keeps buying this thing?

[236T568]

Based on the info that is publicly available for SKBI, it just does not look good for the non-insider stockholders of this company

[tbirdman]

Weeee

[tbirdman]

??

[236T568]

Someone knows something and that "something" is not a good thing

[236T568]

Yikes! $0.98 - Lowest price since October 8th

[236T568]

here you go...

says that the NASDAQ hearing panel might take 2-4 weeks to announce the decision:

http://nasdaq.cchwallstreet.com/nasdaq/main/nasdaq-equityrules/chp_1_1/chp_1_1_4/chp_1_1_4_3/chp_1_1_4_3_10/chp_1_1_4_3_10_6/default.asp

Apparently a NASDAQ hearing panel takes 2-4 weeks for a decision after the hearing...

[tbirdman]

Apparently a NASDAQ hearing panel takes 2-4 weeks for a decision after the hearing...

[modes948]

No news about what happened Dec3?